Takeda and Lundbeck announced that Trintellix (vortioxetine) formerly Brintellix, is now available following an FDA announcement regarding product name confusion.
On May 2, 2016, it was announced that Brintellix, an antidepressant, would be renamed to Trintellix to avoid name confusion in the marketplace with the antiplatelet Brilinta (ticagrelor; AstraZeneca). The Food and Drug Administration (FDA) had identified a total of 55 cases involving trade name confusion between these two drugs. Two of the five recent cases led to serious adverse drug events: one patient had bleeding and partial collapse of a lung following a lung biopsy after receiving Brilinta instead of Brintellix; another patient experienced a fall and was hospitalized after ingesting Brintellix instead of Brilinta. The Companies, in coordination with the FDA, concluded that a name change would be best to avoid future name confusion among patients and providers.
Trintellix is indicated for the treatment of major depressive disorder in adults and is available in the same formulation and dosage strengths as Brintellix: 5mg, 10mg, 15mg, and 20mg strength tablets. The Trintellix tablet markings are identical to that of Brintellix. However, Trintellix will be designated a new National Drug Code (NDC) number.
For more information call (877) TAKEDA-7 or visit Trintellix.com.